Zobrazeno 1 - 10
of 4 346
pro vyhledávání: '"neoadjuvant treatment"'
Publikováno v:
Journal of Hepatocellular Carcinoma, Vol Volume 11, Pp 1581-1595 (2024)
Guimin Hou,1,* Feng Zhang,1,* Xielin Feng,1 Yan Chen,2 Jinliang Zhang,1 Haiqing Wang1 1Department of Hepatopancreatobiliary Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital and Institute, Affiliated Cancer Hospita
Externí odkaz:
https://doaj.org/article/d166c332658e4c0782cd2ebe1f593abe
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 525-547 (2024)
Abstract Introduction The phase III randomized KEYNOTE-522 trial demonstrated that pembrolizumab in combination with chemotherapy as neoadjuvant treatment followed by adjuvant pembrolizumab (pembrolizumab + chemotherapy) provided significant improvem
Externí odkaz:
https://doaj.org/article/499f6d95549e4000968fd31438b2f8fc
Publikováno v:
Thoracic Cancer, Vol 15, Iss 19, Pp 1471-1476 (2024)
Abstract Background Antiangiogenic treatment and immunochemotherapy effectively treat patients with advanced esophageal cancer. However, there remains a dearth of studies concerning neoadjuvant therapy for resectable esophageal cancer. Methods The st
Externí odkaz:
https://doaj.org/article/9262f5bee9594e40ac6b7dc985b84c8b
Autor:
Da Hyun Kang, Chaeuk Chung
Publikováno v:
Tuberculosis and Respiratory Diseases, Vol 87, Iss 3, Pp 292-301 (2024)
Stage 3 non-small cell lung cancer (NSCLC) exhibits significant diversity, making it challenging to define an optimal treatment. A collaborative multidisciplinary approach is essential in crafting individualized treatments. Previously, targeted thera
Externí odkaz:
https://doaj.org/article/f97ed71b962841838706f1c860f4acdc
Autor:
Fabio Canino, Monica Barbolini, Ugo De Giorgi, Tommaso Fontana, Valeria Gaspari, Caterina Gianni, Lorenzo Gianni, Antonio Maestri, Santino Minichillo, Luca Moscetti, Antonella Mura, Stefania Vittoria Luisa Nicoletti, Claudia Omarini, Rachele Pagani, Samanta Sarti, Angela Toss, Claudio Zamagni, Riccardo Cuoghi Costantini, Federica Caggia, Giuseppina Antonelli, Federica Baglio, Lorenzo Belluzzi, Giulio Martinelli, Salvatore Natalizio, Ornella Ponzoni, Massimo Dominici, Federico Piacentini
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-18 (2024)
Abstract Background The addition of pertuzumab (P) to trastuzumab (H) and standard chemotherapy (CT) as neoadjuvant treatment (NaT) for patients with HER2 + breast cancer (BC), has shown to increase the pathological complete response (pCR) rate, with
Externí odkaz:
https://doaj.org/article/1ac6fc48a61047d696aefc89f35bee02
Publikováno v:
Chinese Journal of Lung Cancer, Vol 27, Iss 5, Pp 383-390 (2024)
Lung cancer is still the leading cause of cancer death worldwide. Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, accounting for about 80%. Approximately 30% of all patients with NSCLC have resectable early and middle
Externí odkaz:
https://doaj.org/article/60cb89985369406083b5edc922a2c1cc
Publikováno v:
Cancer Medicine, Vol 13, Iss 18, Pp n/a-n/a (2024)
Abstract Background The optimal duration of preoperative imatinib (IM) remains controversial. This study aimed to evaluate the safety, therapeutic effectiveness, and optimal duration of preoperative IM in patients with locally advanced gastric gastro
Externí odkaz:
https://doaj.org/article/5e650198d19843b39d108318598a2852
Autor:
Bengt Glimelius, Tanweera Khan, Karin Adolfsson, Eva Angenete, Åke Berglund, Kristina Bonde, Nils Elander, Tone Fokstuen, Johan Haux, Israa Imam, Cecilia Lagerbäck, Ingrid Ljuslinder, Andrzej Piwowar, Marie Zajicova, Per J. Nilsson
Publikováno v:
EClinicalMedicine, Vol 75, Iss , Pp 102771- (2024)
Summary: Background: Total neoadjuvant treatment (TNT) for locally advanced rectal cancer (LARC) increases pathologic complete response (pCR) rate and reduces the risk of systemic recurrences over chemoradiotherapy (CRT) in randomised trials, e.g., t
Externí odkaz:
https://doaj.org/article/e883f34623c44a3b9ec58bd2e18a9b0d
Publikováno v:
Acta Medica Lituanica, Vol 31, Iss 1 (2024)
Administering checkpoint inhibition before surgery, known as neoadjuvant therapy, shows promise in treating bulky yet resectable melanomas, and researchers are investigating its potential in various other cancer types. This approach boasts a consider
Externí odkaz:
https://doaj.org/article/24851ed7f73a40a980c342fd97a5f8bf
Autor:
Zhidong Lyu, Linlin Gao
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundThis study aimed to retrospectively analyse the pathological response and safety of combining albumin-bound paclitaxel (nab-paclitaxel) or docetaxel with anti-HER2 therapy as a neoadjuvant treatment for HER2-positive breast cancer.MethodsFr
Externí odkaz:
https://doaj.org/article/44100500657041aba6b251e2117f08e1